GlassScriptPhysician profile
Raza M Khan
NPI 1568455327
$4,142.34
in general payments reported to CMS, 2019-2025
38 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $129 · 2021: $349 · 2022: $744 · 2023: $606 · 2024: $1,160 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931 · Travel and Lodging: $438 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.19 |
| Travel and Lodging | $437.55 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,063.96 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Abbvie INC. | $852.07 | 2019-2025 | |
| Olympus America INC. | $240.32 | 2022-2024 | Soltive, Olympus, Itind System |
| Profound Medical Corp. | $217.40 | 2022-2025 | Tulsa-Pro |
| Rochester Medical Corporation | $168.66 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $160.74 | 2024-2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $136.96 | 2019-2022 | |
| Agiliti Surgical, INC. | $122.97 | 2025 | Siemens Healthineers Varian Cryocare, Sonablate Hifu, Koelis Trinity Mri/US Fusion |
| Pfizer INC. | $113.43 | 2019 | |
| Coloplast Corp | $112.64 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $98.72 | 2023-2025 | Gemtesa, Orgovyx |
| Antares Pharma, INC. | $90.45 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $76.23 | 2019-2021 | |
| Janssen Biotech, INC. | $65.39 | 2019 | |
| Boston Scientific Corporation | $52.96 | 2020-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.88 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $44.93 | 2023 | Spravato |
| Laborie Medical Technologies Corp. | $40.47 | 2024 | Urgent PC Neuromodulation System |
| Neotract INC. | $39.03 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Springworks Therapeutics, INC. | $34.75 | 2024 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $33.61 | 2025 | Provenge |
| Immunitybio, INC. | $32.08 | 2024 | |
| Endo Pharmaceuticals INC. | $31.92 | 2022-2023 | Xiaflex, Aveed |
| Janssen Scientific Affairs, LLC | $30.06 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $29.40 | 2019-2020 | |
| Abc Home Medical Supply, INC. | $26.29 | 2022 | |
| Avation Medical, INC. | $23.07 | 2024 | Vivally |
| Verity Pharmaceuticals INC. | $18.99 | 2022 | |
| Tolmar, INC. | $17.94 | 2025 | Eligard |
| Ethicon US, LLC | $17.87 | 2021 | |
| Medtronic, INC. | $17.35 | 2024 | Intellis Adaptivestim |
| Urogen Pharma, INC. | $15.69 | 2023 | Jelmyto |
| Exelixis INC. | $15.35 | 2019 | |
| Urovant Sciences INC | $11.84 | 2022 | |
| Clarus Therapeutics INC. | $4.86 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.